A Department of Health and Human Services spokesperson called the move "a radical departure from past practices." ...

Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Tresidder said his Melbourne-based firm has “a real focus” on biotech and life sciences. He sketched some of the ways brokers ...

The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31 December ...

Lakshmi Priya Darshini Pulavarthi blends scientific expertise with data management to drive clinical trial success across oncology, hematology, and cardiovascular therapeutic areas.

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I clinical trial, according to results presented by Kathryn C. Arbour, ...